Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody 279

Antibody Genotype Licensing Licensing 279

Fierce Pharma

OCTOBER 5, 2023

Lonza has extended a long-term collaboration with an unnamed “major global biopharmaceutical partner” to crank up commercial supply of antibody-drug conjugates at its site in Visp, Switzerland. The abrupt departure of Lonza’s CEO last month clearly hasn’t dampened the Swiss CDMO’s dealmaking prowess.

Antibody 102

Antibody Production Drugs 102

Pharmaceutical Technology

JULY 13, 2023

US FDA granted the IgG1 monoclonal antibody the first qualified infectious disease product (QIDP) designation.

Antibody 130

Antibody Production 130

Pharmaceutical Technology

MARCH 9, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.

Antibody 147

Antibody Production Protein Regulation 147

Pharmaceutical Technology

AUGUST 29, 2022

Sanyou Biopharmaceuticals and Shanghai KangaBio have signed a licencing agreement to expedite the development and innovation of the former’s monoclonal antibody drug. The latest deal will grant KangaBio an exclusive licence for the use of the antibody to carry out research, development, production and marketing of immunotherapy products.

Antibody 130

Antibody Development Drugs Production 130

Drug Discovery World

MAY 1, 2024

DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Many of the best-selling drugs in 2023 were monoclonal antibody (mAB) therapies, including Keytruda (pembrolizumab), Humira (adalimumab), and Dupixent (dupilumab) 1.

Antibody 59

Antibody FDA Approval Drugs Development 59

Drug Discovery World

MARCH 12, 2024

Here, experts weigh in on the future of monoclonal antibodies (mAbs). Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates. Innovations include next-generation antibodies with improved efficacy and reduced side effects.

Antibody 82

Antibody FDA Approval Drugs Development 82

XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

Drug Discovery World

SEPTEMBER 12, 2023

Twist Bioscience and Ono Pharmaceutical will combine their efforts to discover and develop novel antibodies for the treatment of autoimmune diseases. Under the terms of the agreement, Twist will use its ‘Library of Libraries’ to conduct research activities to discover novel antibodies against targets identified by Ono.

Antibody 73

Antibody Sales Production Development 73

Pharma Mirror

APRIL 18, 2023

Dudley, UK, April 18th 2023: Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).

Licensing 130

Licensing Licensing Manufacturing Antibody 130

Pharmaceutical Technology

OCTOBER 19, 2022

Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. . Eucure will oversee the production and delivery of the drug, while Syncromune will handle the clinical development and marketing.

Antibody 130

Antibody Licensing Licensing Containment 130

Pharmaceutical Technology

OCTOBER 12, 2022

Biotech start-up Toregem BioPharma has signed a memorandum of understanding (MoU) with WuXi Biologics to develop the monoclonal antibody, TRG035. Additionally, WuXi Biologics will help the company with the development of the anti-USAG-1 antibody for Investigational New Drug (IND) application.

Antibody 130

Antibody Development Bioassay Manufacturing 130

Pharmaceutical Technology

NOVEMBER 16, 2022

Clinical-stage biopharmaceutical companies NextCure and LegoChem Biosciences have signed a collaboration and co-development agreement to develop a B7-H4 antibody drug conjugate (ADC), and features options for two further targets. Furthermore, the agreement has options to designate two more targets for ADC development other than B7-H4 ADC.

Antibody 130

Antibody Development Drugs Production 130

Fierce Pharma

SEPTEMBER 18, 2023

After inking and expanding a biosimilar production partnership with Pfizer this summer, Korea’s Samsung Biologics is boosting yet another Big Pharma manufacturing agreement. Samsung Biologics has inked a new deal with Bristol Myers Squibb for large-scale drug substance production on an unnamed commercial cancer antibody.

Antibody 84

Antibody Manufacturing Production Drugs 84

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The company will also be eligible for tiered royalties as a percentage of global commercial sales of the products.

Antibody 130

Antibody Development Drugs Licensing 130

Pharmaceutical Technology

JANUARY 18, 2023

The National Medical Products Administration (NMPA) of China has approved Shanghai Henlius Biotech ’s monoclonal antibody Hansizhuang (serplulimab injection) along with carboplatin and etoposide to treat extensive stage small cell lung cancer (ES-SCLC).

Antibody 130

Antibody Drugs Production Marketing 130

Pharmaceutical Technology

AUGUST 16, 2023

AGC has entered into an agreement with Asahi Kasei to produce clinical drug substance for antibody-based therapies at its Seattle site.

Production 130

Production Drugs Antibody 130

Pharmaceutical Technology

JULY 20, 2022

TSB Therapeutics, a joint venture (JV) majority-owned by Brii Biosciences (Brii Bio), has entered a collaboration with China Resources Pharmaceutical Commercial Group (CR Pharma) for the commercialisation of an antibody therapy, amubarvimab/romlusevimab combination, for Covid-19 in China. .

Antibody 147

Antibody Life Science Production Development 147

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. To overcome this challenge, Synaffix has developed an innovative technology platform that can rapidly and efficiently convert any antibody into an ADC.

Antibody 98

Antibody Marketing Drugs Licensing 98

Drug Discovery World

FEBRUARY 15, 2024

DDW Editor Reece Armstrong speaks to Tracy M Woody , President and Chief Executive Officer of Cessation Therapeutics, about the company’s goal to develop an antibody therapy to prevent fentanyl overdoses. As it stands, there are no FDA-approved products designed to prevent a fentanyl overdose.

Antibody 59

Antibody FDA Approval Drugs Development 59

BioSpace

SEPTEMBER 24, 2023

After dropping an early-stage study more than a year ago, AbbVie has finally terminated its CD47 collaboration with I-Mab, leaving up to $1.3 billion in potential milestone payments on the table.

Antibody 88

Antibody Production 88

Pharmaceutical Technology

AUGUST 1, 2023

The China National Medical Products Administration (NMPA) has accepted Astellas Pharma’s biologics licence application for zolbetuximab.

Antibody 130

Antibody Production 130

Drug Discovery World

FEBRUARY 22, 2024

Microbial control within biopharmaceutical manufacturing is a critical quality control to help ensure drug products are free from viable microorganisms. The post Webinar: Environmental monitoring within biotherapeutic production appeared first on Drug Discovery World (DDW).

Production 52

Production Genotype Manufacturing Gene Therapy 52

Roots Analysis

FEBRUARY 27, 2024

Ambrx and NovoCodex Biopharmaceuticals announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates. The antibody drug conjugates market is expected to grow at a CAGR of ~10% during the forecast period. Check the details of the agreement here.

Antibody 40

Antibody Marketing Drugs Contract Manufacturing 40

Fierce Pharma

MARCH 15, 2024

Novartis broke ground on a $256 million expansion of its biopharmaceutical production facility in Singapore. The project will introduce digitalization and automation at the site in a bid to boost manufacturing productivity and to help upskill the company’s workforce.

Antibody 114

Antibody Manufacturing Production 114

Drug Discovery World

FEBRUARY 15, 2024

Microbial control within biopharmaceutical manufacturing is a critical quality control to help ensure drug products are free from viable microorganisms. The post Webinar: Understand microbial control in biotherapy production appeared first on Drug Discovery World (DDW).

Production 52

Production Genotype Manufacturing Gene Therapy 52

Drug Discovery World

NOVEMBER 29, 2022

Join DDW for this exclusive free event : Accessing Broad B Cell Diversity to Rapidly Identify High-Value Rabbit Monoclonal Antibodies. What you will learn: How to accelerate the discovery of novel antibodies for research and drug discovery purposes. Register free here.

Antibody 52

Antibody Production Drugs Research 52

Drug Discovery World

NOVEMBER 22, 2022

Join DDW for this exclusive free event : Accessing Broad B Cell Diversity to Rapidly Identify High-Value Rabbit Monoclonal Antibodies. What you will learn: How to accelerate the discovery of novel antibodies for research and drug discovery purposes. Register free here.

Antibody 52

Antibody Production Drugs Research 52

Drug Discovery World

NOVEMBER 27, 2023

As the significance of large molecules continues to broaden across diverse modalities, emphasis on bispecific and multispecific antibodies to treat various disorders such as rheumatologic diseases, cancer, diabetes, anaemia, and infectious diseases becomes paramount. Biotechnol Bioeng 2012;118:2326. Budge JD, Knight TJ, Povey J, et al.

Production 59

Production Engineer Gene Editing Gene 59

Drug Discovery World

JULY 24, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation for Janssen’s Talvey (talquetamab). The post CHMP recommendation for bispecific antibody talquetamab appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Licensing Licensing Medicine 52

Drug Discovery World

OCTOBER 12, 2023

targeting antibody with improved CLDN18.2 binding affinity and enhanced antibody-dependent cellular cytotoxicity (ADCC). The interim safety, clinical pharmacology and efficacy data we presented fostered a productive dialogue with the FDA. Osemitamab is a second-generation humanised CLDN18.2 expression. “The

Antibody 52

Antibody Trials Drugs Medicine 52

Drug Discovery World

OCTOBER 4, 2022

Currently, at least 35 glycoengineered antibodies, with their Fc fucose partially or entirely removed, have been investigated in animal models or clinical trials. It results in increased antibody-dependent cellular cytotoxicity (ADCC). Download this app note to learn more about: How antibodies work to eliminate the antigens.

Antibody 52

Antibody Clinical Trials Clinical Trials Production 52

Drug Discovery World

DECEMBER 6, 2022

Join DDW for this exclusive free event : Accessing Broad B Cell Diversity to Rapidly Identify High-Value Rabbit Monoclonal Antibodies. What you will learn: How to accelerate the discovery of novel antibodies for research and drug discovery purposes. Register free here.

Antibody 52

Antibody Production Drugs Research 52

Drug Discovery World

MAY 25, 2023

Several new products for the life sciences sector have been launched over the last month, from miniature semiconductor chip (MSC) technology to a new inhalation testing service. Astera Software: Astera API Management The new product is a no-code, automated, unified platform for complete API lifecycle management and integrations.

Production 52

Production Reagent DNA Drugs 52

BioTech 365

JUNE 25, 2021

Global Antibody Production Market Research Report 2021: Market to Reach $26.1 Billion by 2027 – Monoclonal Antibody Segment to Surpass $20 Billion – ResearchAndMarkets.com Global Antibody Production Market Research Report 2021: Market to Reach $26.1

Antibody 40

Antibody Marketing Production Research 40

Drug Discovery World

OCTOBER 4, 2022

Currently, at least 35 glycoengineered antibodies, with their Fc fucose partially or entirely removed, have been investigated in animal models or clinical trials. It results in increased antibody-dependent cellular cytotoxicity (ADCC). Download the new App Note to learn more about: How antibodies work to eliminate the antigens.

Antibody 52

Antibody Clinical Trials Clinical Trials Production 52

Drug Discovery World

OCTOBER 11, 2023

Collaborators Boehringer Ingelheim and CDR-Life have commenced a Phase I evaluation of BI 771716, their antibody fragment-based treatment developed to preserve the vision of people with geographic atrophy (GA).

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Trials 52